Product Overview
Dermacell is a technologically advanced human acellular dermal matrix. Dermacell is decellularized using Matracell®, a proprietary, patented, and validated processing technology that removes cells and ≥ 97% of donor DNA without compromising the desired biomechanical or biochemical properties of the graft and allowing for rapid cellular infiltration and re-vascularization. Dermacell is ready to use out of the package and stored at room temperature, eliminating the need for refrigeration and rehydrating processes. As a final step, all Dermacell grafts are terminally sterilized – rendering the graft sterile to medical device‑grade standards with a Sterility Assurance Level (SAL) of 10-6, or a 1 in 1 million chance of the presence of a single viable microorganism on the graft.
Benefits
• Biohospitable: Cells and ≥ 97% DNA removed to potentially minimize any adverse patient response
• Intact Acellular Framework: Retains native growth factors, collagen and elastin
• Room Temperature Storage: Ready to use out of the package
• Strength: Pull-out strength and load to failure are comparable to native dermis
• Sterile: Sterilized to a Sterility Assurance Level (SAL) of 10-6; medical device grade sterility
• Structural Support: Facilitates cell proliferation and migration; critical for wound management
• Conducted the largest randomized controlled trial (RCT) to date using hADM in chronic wounds
Clinical Application
Dermcell AWM
• Chronic Wounds* – Diabetic foot ulcers (DFUs), venous stasis ulcers (VSUs), arterial ulcers, pressure ulcers, dehisced surgical wounds, traumatic burns
* Dermacell can be used over exposed tendon, bone, joint capsule, and muscle (https://www.lifenethealth.org)
